Discover 223 paid clinical trials in Knoxville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 223
Active & Responsive
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
for
Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
for
Carcinoma, Non-Small-Cell Lung
Location: 40 recruiting locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06623422
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
for
Emphysema, Pulmonary, Emphysema or COPD
Location: 13 recruiting locations
Sponsor: Pulmonx Corporation
Sex: All
Age: 40 - 70+
Code: NCT06035120
Recruiting
Active & Responsive
Early Childhood Dietary Assessment Study
for
Dietary Assessment
Location: 1 recruiting location
Sponsor: The University of Tennessee, Knoxville
Sex: All
Age: 2 - 5
Code: NCT07227272
Recruiting
Active & Responsive
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
for
PIK3CA Mutation, HER2- Negative Breast Cancer,
Location: 25 recruiting locations
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06982521
Phase3, Recruiting
Active & Responsive
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer,
Location: 13 recruiting locations
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All
Age: 18+
Code: NCT06901531
Phase3, Recruiting
Active & Responsive
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)